Unlocking Precision Medicine at Scale: AI-Driven Solutions to Advance BioPharma Development and Commercialization

Scientific innovation and the unprecedented surge in health data generated every day are transforming our understanding of disease and reshaping the future of precision medicine. As FDA-approved biomarker-targeted therapies continue to expand rapidly, BioPharma companies face increasing pressure to bring them to the market faster to the patients who need them the most. As such, the delivery of robust, accurate, and scalable end-to-end diagnostic solutions across the globe has become essential. 

In this talk, we will explore how SOPHiA GENETICS empowers BioPharma to advance precision medicine by harnessing AI-powered analytics and next-generation genomics solutions, improving access to new therapies worldwide and helping close critical health equity gaps. 

• Explore current patient identification challenges across the drug development process and practical implementation models to address them, while navigating an evolving regulatory landscape.

• Discover how to unlock SOPHiA DDM™ potential to optimize and accelerate drug development and commercialization by combining AI-powered technology, a vast decentralized network, and a comprehensive portfolio of NGS-based assays.

• Learn about our groundbreaking partnerships that enable faster, more efficient, and scalable CDx development and commercialization.